XML 56 R47.htm IDEA: XBRL DOCUMENT
v3.24.3

Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Jun. 30, 2024 | Jan. 31, 2024 | Oct. 31, 2023 | Jul. 31, 2023 | Feb. 28, 2023 | Jan. 31, 2023 | Jan. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2018 | Sep. 30, 2017 | Mar. 31, 2017 | Mar. 31, 2016 | Feb. 28, 2015 | Sep. 30, 2024 | Jun. 30, 2024 | Sep. 30, 2023 | Jun. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2018 | Dec. 31, 2022
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,900,000 |  | $ 15,000,000 |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,850,000 | $ 15,372,000 |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 42,298,000 |  | $ 66,056,000 |  | 166,308,000 | 232,198,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,974,000 |  |  | 4,974,000 | $ 4,850,000 |  | $ 15,346,000
Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 41,852,000 |  | 64,903,000 |  | 144,522,000 | 214,744,000 |  |  |
Marine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,900,000 |  |  |  |  |
Mochida Pharmaceutical Co., Ltd. | In-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones payment |  |  | $ 1,000,000 |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Up-front payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,700,000 |
Edding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 |  | 5,000,000 |  |  |  |  |
Edding | Achievement of REDUCE-IT Trial | VASCEPA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Edding | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable up-front received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |
Sales-based milestone event payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 120,000,000 |  |  |  | 120,000,000 |  |  |  |
Revenue recognized related to upfront and milestone payments | [1] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,400,000 |  |  |
Revenue recognized related to upfront and milestone payments | [1] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,426,000 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,400,000 |  |
Edding | Out-licenses | Licensing Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40,081,000 |  | $ 20,655,000 |  |
Edding | Out-licenses | Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,800,000 |  | 300,000 |  | 8,200,000 | 300,000 |  |  |
Edding | Out-licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales-based milestone event payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  | 50,000,000 |  |  |  |
Edding | Out-licenses | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales-based milestone event payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000,000 |  |  |  | 5,000,000 |  |  |  |
Edding | Out-licenses | Clinical Trial Application |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |
Edding | Out-licenses | Achievement of REDUCE-IT Trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Edding | Out-licenses | Marine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,900,000 |  |  |  |  |
Additional license revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 |  | 5,000,000 |  | 4,000,000 | 5,000,000 |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |  |
Remaining performance period amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,100,000 |  |  |  | 1,100,000 |  |  |  |
Reduction in net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000 | 5,000,000 |  |  |
Edding | Out-licenses | Marine | VASCEPA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |
Edding | Out-licenses | Marine | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition period of non-refundable up-front payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |
Edding | Out-licenses | Marine | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition period of non-refundable up-front payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11 years |  |  |  |
Biologix FZCo |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition period of non-refundable up-front payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 years |  |  |  |
Biologix FZCo | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,300,000 |  |  |
Reduction in net loss |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,300,000 |  |  |
Biologix FZCo | Out-licenses | Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,300,000 |  | 1,400,000 |  | $ 1,300,000 | 2,000,000 |  |  |
HLS |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,300,000 |  |  |  |  |
HLS | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable up-front received |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  |  |  |  |  | $ 3,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized related to upfront and milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,600,000 |  |  |
HLS | Out-licenses | Health Canada |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
HLS | Out-licenses | Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | 1,900,000 | 1,600,000 |  |  |
HLS | Out-licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone |  |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |
HLS | Out-licenses | Achievement of REDUCE-IT Trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable milestone payment received |  |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |
CSL Seqirus | Out-licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable up-front received |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 500,000 |  |  |
Upfront payment receivable |  |  |  |  |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Event-related milestone payments receivable |  |  |  |  |  | 8,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional product-related milestone payments receivable |  |  |  |  |  | $ 4,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CSL Seqirus | Out-licenses | Product Revenue, Net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 800,000 |  |  |  | $ 800,000 |  |  |  |
Lotus Pharmaceuticals | VAZKEPA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable up-front received |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment receivable |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lotus Pharmaceuticals | Out-licenses | Licensing Revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  | $ 300,000 |  |  |
[1] | Licensing revenue under the DCS Agreement is recognized concurrent with the input measure of support hours provided by Amarin to Edding in achieving the combined development and regulatory performance obligation, which in the Company’s judgment is the best measure of progress towards satisfying this performance obligation.

X
- Definition Additional license revenues upfront payment and prior year milestone payments. + References No definition available. + Details
Name: | amrn_AdditionalLicenseRevenuesUpfrontPaymentAndPriorYearMilestonePayments
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional milestone payments to be received. + References No definition available. + Details
Name: | amrn_AdditionalMilestonePaymentsToBeReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional product-related milestone payments receivable. + References No definition available. + Details
Name: | amrn_AdditionalProductRelatedMilestonePaymentsReceivable
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Contract with customer liability revenue recognized including opening balance + References No definition available. + Details
Name: | amrn_ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated number of days following the end of the quarter before related revenue is recognized. + References No definition available. + Details
Name: | amrn_DeferredRevenueRecognitionPeriod
Namespace Prefix: | amrn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Eligible event related milestone payments to be received. + References No definition available. + Details
Name: | amrn_EligibleEventRelatedMilestonePaymentsToBeReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Eligible sales based milestone events to be received. + References No definition available. + Details
Name: | amrn_EligibleSalesBasedMilestoneEventsToBeReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition License And Collaboration Agreements [Line Items] + References No definition available. + Details
Name: | amrn_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | amrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable and non-creditable upfront payment. + References No definition available. + Details
Name: | amrn_NonRefundableAndNonCreditableUpfrontPayment
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non refundable upfront payments received. + References No definition available. + Details
Name: | amrn_NonRefundableUpfrontPaymentsReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Nonrefundable milestone payment received. + References No definition available. + Details
Name: | amrn_NonrefundableMilestonePaymentReceived
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment of milestone. + References No definition available. + Details
Name: | amrn_PaymentOfMilestones
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reduction in net loss. + References No definition available. + Details
Name: | amrn_ReductionInNetLoss
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront payment receivable. + References No definition available. + Details
Name: | amrn_UpfrontPaymentReceivable
Namespace Prefix: | amrn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=amrn_MarineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_MochidaPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=amrn_InLicensesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_EddingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=amrn_AchievementOfReduceItTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amrn_VascepaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=amrn_OutLicensesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=amrn_ClinicalTrialApplicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_BiologixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_HLSTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RegulatoryAgencyAxis=amrn_HealthCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_CslSeqirusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | amrn_BusinessDevelopmentsAxis=amrn_LotusPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amrn_VazkepaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |